[Internship] Translational Pharmacology & Microbiology

Join our Translational Pharmacology team, based in Paris, as an intern (for a minimum period of 5 months) and contribute to the development of innovative preclinical models to test the efficacy of Eligobiotics®. You will be supervised by a translational scientist specialized in skin immunology and microbiology, and work closely with an international team at the interface of microbiology and drug development.

Eligo Bioscience develops a new class of biotherapeutics called Eligobiotics® that enable precision-editing of the microbiome. These phage-derived particles deliver synthetic DNA payloads into bacteria in situ. Eligobiotics® are developed for three types of applications:

1. Sequence-specific antimicrobials: Eligobiotics® deliver a DNA payload into specific bacteria, which then express a CRISPR-Cas complex. An RNA guides the CRISPR-Cas complex to a specific complementary DNA sequence (target sequence), causing double-strand breaks and the subsequent death of the bacteria. Only bacteria carrying the specific target DNA sequence are killed, while other bacteria remain intact.

2. Gene editing: Eligobiotics® deliver a DNA payload into specific bacteria, which then express a base editor complex. An RNA guide steers the base editor complex to a specific complementary DNA sequence (target sequence), leading to the substitution of a selected nucleotide with another. Specific mutations can be introduced without killing the bacteria.

3. Function addition to the microbiome: Eligobiotics® deliver a DNA payload into specific bacteria, which then express one or multiple transgenes of interest. The protein of interest is typically a therapeutic protein.